Schizophrenia and bipolar disorders are serious psychiatric disorders with substantial health risks. Asenapine is a new secondgeneration antipsychotic, available as a sublingual tablet, approved in Europe for the treatment of moderate-to-severe manic episodes in adults, and in US for manic or mixed episodes of bipolar I disorder in adults and adolescents. In this review, we searched the available literature to appreciate the role of asenapine in the management of psychiatric conditions such as bipolar disorders and schizophrenia and describe its mechanism of action, efficacy and tolerability. Asenapine has demonstrated efficacy in the management of bipolar disorders and schizophrenia, while a possible role in the management of borderline pe...
Over the years, both first- (FGAs) and second-generation antipsychotics (SGAs), continue to gain inc...
The aim of this study was to quantitatively review, using a meta-analytic approach, randomized-cont...
Jodi M Gonzalez1, Peter M Thompson1, Troy A Moore1,21University of Texas Health Science Center, San ...
Schizophrenia and bipolar disorders are serious psychiatric disorders with substantial health risks....
Maurizio Pompili1,2, Paola Venturini1, Marco Innamorati1, Gianluca Serafini1, Ludovica Telesforo1, D...
Asenapine is a new antipsychotic drug, approved by the FDA in 2009 for the acute treatment of schizo...
Schizophrenia is a chronic brain disorder comprising a range of clinical features, including positiv...
Abstract INTRODUCTION: Asenapine is a sublingually administered second-generation antipsychotic ...
Introduction: Bipolar I disorder (BDI) is amongst the most debilitating psychiatric conditions with ...
Calvert G Warren,1 Steven L Dubovsky1,21Department of Psychiatry, State University of New York at Bu...
Bipolar disorder is a chronic mental illness associated with high levels of somatic morbidity, comor...
Introduction: Several randomized controlled trials (RCTs), conducted in schizophrenic and bipolar pa...
Asenapine is a second-generation (atypical) antipsychotic medication not available in a pill that ca...
Asenapine is a second-generation (atypical) antipsychotic medication not available in a pill that ca...
Leslie CitromeNew York University School of Medicine, Department of Psychiatry, New York, NY, USAAbs...
Over the years, both first- (FGAs) and second-generation antipsychotics (SGAs), continue to gain inc...
The aim of this study was to quantitatively review, using a meta-analytic approach, randomized-cont...
Jodi M Gonzalez1, Peter M Thompson1, Troy A Moore1,21University of Texas Health Science Center, San ...
Schizophrenia and bipolar disorders are serious psychiatric disorders with substantial health risks....
Maurizio Pompili1,2, Paola Venturini1, Marco Innamorati1, Gianluca Serafini1, Ludovica Telesforo1, D...
Asenapine is a new antipsychotic drug, approved by the FDA in 2009 for the acute treatment of schizo...
Schizophrenia is a chronic brain disorder comprising a range of clinical features, including positiv...
Abstract INTRODUCTION: Asenapine is a sublingually administered second-generation antipsychotic ...
Introduction: Bipolar I disorder (BDI) is amongst the most debilitating psychiatric conditions with ...
Calvert G Warren,1 Steven L Dubovsky1,21Department of Psychiatry, State University of New York at Bu...
Bipolar disorder is a chronic mental illness associated with high levels of somatic morbidity, comor...
Introduction: Several randomized controlled trials (RCTs), conducted in schizophrenic and bipolar pa...
Asenapine is a second-generation (atypical) antipsychotic medication not available in a pill that ca...
Asenapine is a second-generation (atypical) antipsychotic medication not available in a pill that ca...
Leslie CitromeNew York University School of Medicine, Department of Psychiatry, New York, NY, USAAbs...
Over the years, both first- (FGAs) and second-generation antipsychotics (SGAs), continue to gain inc...
The aim of this study was to quantitatively review, using a meta-analytic approach, randomized-cont...
Jodi M Gonzalez1, Peter M Thompson1, Troy A Moore1,21University of Texas Health Science Center, San ...